Asymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline? - Test2 - elhamkhani - TriplyDB

Asymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?

Asymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?

http://www.wikidata.org/entity/Q28075206

about

Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.Boosting endogenous production of vasoprotective hydrogen sulfide via supplementation with taurine and N-acetylcysteine: a novel way to promote cardiovascular health.Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality.Serum Concentrations of New Predictive Cardiovascular Disease Biomarkers in Mexican Women Exposed to Lead.

P2860

Q37728038-0B7FEB8D-4F71-4E1E-9896-1D1DBA572BF5 Q42338456-E5E59B6C-0413-4F08-90F3-9CE8E78B5746 Q42355197-8B992EB5-F49E-4090-9814-BB9A3A0E1B0A Q47267706-3C5BFBD0-7405-4144-9876-01BFB5C2F759

P2860

Asymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?

http://www.wikidata.org/entity/Q28075206

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@ast

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@en

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@nl

type

label

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@ast

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@en

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@nl

prefLabel

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@ast

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@en

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@nl

P1433

Q28075206-FEC502BE-F9BB-4981-8C62-68D6EBD577E0

P1476

Q28075206-FE699AEE-9E0A-415F-8E41-14FDB8117D0B

P2093

Q28075206-3F3FCFEC-61C3-451C-BB63-8E64F882914D

P2860

Q28075206-00634322-019E-41B5-82F4-BD650AFD0001

Q28075206-05E719CA-4498-4F48-A8A5-9D744783D5DD

Q28075206-062757CD-48E5-4D55-8CDD-5C6107D81BA6

Q28075206-08453746-C497-464A-9BD8-96E867D0E617

Q28075206-0A5CD6DD-BAD6-4BCB-B8CD-7F197D37BD61

Q28075206-0B45FCD1-43F7-407C-8486-810CA18C89AF

Q28075206-11740FDC-D388-42D2-8BA9-BA28DFED62A6

Q28075206-176C2A3F-680B-4AB0-AF48-C8130F2F109E

Q28075206-23DF0EEC-4F86-4E6E-A4FA-DA08E207F1D9

Q28075206-27A5336C-24B4-4A53-91BD-99AFC042211F

P31

Q28075206-E349781D-D8F2-4479-A8AB-69A7431CF731

P3181

Q28075206-915EE539-F0A9-4091-AF5E-8D9480741D2B

P356

Q28075206-92856FCD-7A19-46D9-884D-C0EE0BA468E8

P407

Q28075206-5AAF1CB8-9621-4165-B202-F849A3F98B06

P433

Q28075206-12F2DC8B-B53E-4CEB-B6E3-6E262A150E93

P478

Q28075206-BD0000F1-E8D2-466B-B423-287571C760A1

P577

Q28075206-9853C5FD-42DB-4656-8CD2-41B7058F4B88

P698

Q28075206-A9A4612C-B33B-4F5F-8476-021932DFB897

P921

Q28075206-FED49217-6EE8-4D88-9EF4-10E2A87ABEB6

P932

Q28075206-03A26663-BF2E-47E3-8645-C38F18E1B9C0

P3181

P356

HEALTHCARE4030040

P1433

P1476

Asymmetric Dimethylarginine Is ...... Supplemented with Citrulline?

@en

P2093

Mark McCarty

http://www.w3.org/2001/XMLSchema#string

P2860

Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production

Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering

Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies

Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results

Arginine methylation an emerging regulator of protein function

Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension

Partial eNOS deficiency causes spontaneous thrombotic cerebral infarction, amyloid angiopathy and cognitive impairment.

Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in de

Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.

Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in pomerania.

P31

scholarly article

P3181

4604473

http://www.w3.org/2001/XMLSchema#string

P356

10.3390/HEALTHCARE4030040

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27417628

http://www.w3.org/2001/XMLSchema#string

P921

P932

5041041

http://www.w3.org/2001/XMLSchema#string